SCHEMBL256036

SCHEMBL256036

CC/C=C/c1cccs1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5523562 1.00
SCHEMBL22182586 1.00
SCHEMBL23198921 0.90 HCAR2 (0.43)
SCHEMBL23671880 0.90 HCAR2 (0.43)
SCHEMBL23671855 0.90 HCAR2 (0.43)
SCHEMBL23671857 0.90 HCAR2 (0.43)
SCHEMBL13618771 0.83 HCAR2 (0.48)
SCHEMBL21392011 0.80 MAPT (0.51)
SCHEMBL20634195 0.80 MAPT (0.51)
SCHEMBL3688382 0.80 MAPT (0.51)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1633704-A2 INTERMEDIATES USEFUL IN THE SYNTHESIS OF HIV-PROTEASE INHIBITORS AND METHODS FOR PREPARING THE SAME PFIZER INC. (US) 2006-03-15 EP claimed
US-20050250949-A1 Intermediates useful in the synthesis of HIV-protease inhibitors and methods for preparing the same AGOURON PHARMACEUTICALS INC. 2005-11-10 US claimed
WO-2004099129-A2 INTERMEDIATES USEFUL IN THE SYNTHESIS OF HIV-PROTEASE INHIBITORS AND METHODS FOR PREPARING THE SAME PFIZER INC. (US) 2004-11-18 WO claimed
US-10611732-B2 HIV replication inhibiting pyrimidines JANSSEN PHARMACEUTICA NV (BE) 2020-04-07 US disclosed
US-20190322628-A1 HIV REPLICATION INHIBITING PYRIMIDINES JANSSEN PHARMACEUTICA NV (BE) 2019-10-24 US disclosed
US-9765065-B2 Therapeutic substituted cyclopentanes ALLERGAN, INC. (US) 2017-09-19 US disclosed
US-20170144999-A1 THERAPEUTIC SUBSTITUTED CYCLOPENTANES ALLERGAN, INC. 2017-05-25 US disclosed
EP-2285775-B1 Lactams and their use in the treatment of inter alia ocular hypertension or baldness ALLERGAN INC (US) 2017-03-22 EP disclosed
US-9591935-B2 Therapeutic substituted cyclopentanes ALLERGEN, INC. (US) 2017-03-14 US disclosed
EP-2593493-B1 CONJUGATED POLYMERIC SYSTEMS AND APPLICATIONS THEREOF UNIV WAKE FOREST (US) 2017-01-25 EP disclosed
US-9365485-B2 Substituted arylcyclopentenes as therapeutic agents ALLERGAN, INC. (US) 2016-06-14 US disclosed
US-20080058387-A1 5-(3-(3-(4-(1-hydroxyhexyl)phenyl)-4-oxo-thiazolidin-2-yl)propyl)thiophene-2-carboxylic acid; prostaglandin agonist; ocular hypotensive agents; post-surgical and post-laser trabeculectomy ocular hypertensive episodes, glaucoma, and as presurgical adjuncts ALLERGAN, INC. 2008-03-06 US disclosed
US-20080058397-A1 5-(3-(3-(4-hexanoylphenyl)-2,5-dioxoimidazolidin-4-yl)propyl)thiophene-2-carboxylic acid; prostaglandin agonist; ocular hypotensive agent; post-sergical and post-laser trabeculectomy ocular hypertensive episodes, glaucoma, and as presurgical adjuncts OLD DAVID W 2008-03-06 US disclosed
US-20080051374-A1 Therapeutic Amides and related Compounds ALLERGAN, INC. 2008-02-28 US disclosed
US-20080039505-A1 THERAPEUTIC LACTAMS ALLERGAN, INC. 2008-02-14 US disclosed
US-7173059-B2 Intermediates useful in the synthesis of HIV-protease inhibitors and methods for preparing the same AGOURON PHARMACEUTICALS, INC. (US) 2007-02-06 US disclosed
CN-1819993-A Intermediates for the synthesis of HIV-protease inhibitors and processes for their preparation PFIZER (US) 2006-08-16 CN disclosed
EP-1633704-A2 INTERMEDIATES USEFUL IN THE SYNTHESIS OF HIV-PROTEASE INHIBITORS AND METHODS FOR PREPARING THE SAME PFIZER INC. (US) 2006-03-15 EP disclosed
US-20050250949-A1 Intermediates useful in the synthesis of HIV-protease inhibitors and methods for preparing the same AGOURON PHARMACEUTICALS INC. 2005-11-10 US disclosed
WO-2004099129-A2 INTERMEDIATES USEFUL IN THE SYNTHESIS OF HIV-PROTEASE INHIBITORS AND METHODS FOR PREPARING THE SAME PFIZER INC. (US) 2004-11-18 WO disclosed